Mankind Pharma Share Price in Focus; Partners with Chongqing Chenan Biopharmaceutical for Insulin Analogues

On August 20, 2026, Mankind Pharma Limited announced an exclusive agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., China, as per the exchange filings.  

The partnership will aim to focus on distributing advanced insulin analogues in the Indian market. 

Exclusive In-Licensing and Marketing Agreement 

Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd.  

This strategic partnership aims to commercialise Insulin Degludec and Insulin Degludec + Aspart Combination in India, enhancing the company's injectable diabetes portfolio. 

Segment Expansion in India 

Atish Majumdar, Senior President – Sales and Marketing, Mankind Pharma Ltd., said, “China is rapidly emerging as a hub for innovative biopharmaceutical assets. Building on our partnerships for Insulin Aspart and Insulin Degludec, we remain focused on expanding our in-licensing pipeline from China.  

This partnership reinforces our commitment to expanding access to advanced therapies for patients in India while further strengthening our presence in the injectable diabetes segment.” 

Domestic Reach and Infrastructure 

Mankind Pharma operates extensively in Indian pharmaceutical formulations and consumer healthcare sectors. The company has a field force of over 18,500 professionals, reaching more than 5,00,000 doctors across India. It operates 32 production facilities manufacturing tablets, capsules, syrups, and injections. 

Read More: Anupam Rasayan India Share Price in Focus After Q1 FY27 Earnings Results: Total Income Up 36% YoY! 

Research and Development Efforts 

The company drives product innovation through 7 research and development facilities, supported by over 740 expert scientists. This infrastructure underpins Mankind Pharma's commitment to providing high-quality medical products at affordable prices. 

Mankind Pharma Share Price Performance 

As of August 20, 2026, at 3:09 PM, Mankind Pharma share price on NSE was trading at ₹2,380.90, down by 0.55% from the previous closing price. 

Conclusion 

Mankind Pharma's agreement with Chongqing Chenan Biopharmaceutical aims to distribute Insulin Degludec and Insulin Degludec + Aspart Combination in India. The company employs over 18,500 professionals and operates 32 production facilities, enhancing its injectable diabetes portfolio. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.